Objective: The intra-aortic balloon pump (IABP) is an established additional support to pharmacological treatment of the failing heart after myocardial infarction, unstable angina and cardiac surgery. The effect of preoperative IABP in high risk patients was evaluated. Methods: Between June 1994 and March 1996 all high risk patients for CABG (two or more of these criteria: Left ventricular ejection fraction (LVEF) 5 40%, left main stem stenosis ]70%, REDO-CABG, unstable angina) were randomized into either of 3 groups: (1) IABP 1 day prior to surgery, (2) IABP 1 -2 h prior to CPB and (3) no preoperative IABP, controls. Exclusion criteria: cardiogenic shock preoperatively. Fifty-two patients have entered the study -group 1 (13 patients), group 2 (19 patients) and group 3 (20 patients). Preoperative patient characteristics and operative data revealed no group differences. There were 56% REDO's, unstable angina 59%, LVEF540%, 87% (34.0911.6%) and left main stem stenosis in 35%. Results: The CPB-time was shorter in groups 1 and 2 88.79 20.3 min than in group 3 105.5926.8 min, PB 0.001, while ischemia time did not differ. Hospital mortality was higher in group 3, 25% vs. 6% (groups 1 and 2). Postoperative low cardiac output was seen in 12 patients (60%) in group 3 vs. 6 patients (19%) in groups 1 and 2, P B0.05. Cardiac index increased significantly prior to CPB in groups 1 and 2. After CPB cardiac index was significantly higher in groups 1 and 2 compared to Group 3 and continued to increase. The IABP was removed after 3.1 9 1.0 days in group 3 vs. 1.3 90.6 days in groups 1 and 2, P B0.001. In group 3, 11 patients required IABP postoperatively compared to only 4 patients in groups 1 and 2. ICU stay was shorter in groups 1 and 2-2.39 0.9 days vs. 3.591.1 days for group 3, P= 0.004. All patients received dopamin postoperatively, however in a lower dose in groups 1 and 2, 4.5 vs. 13.5 vg/kg/min. Dobutamine was added in 23% of the patients (group 1), 32% (group 2) and 95% (group 3). Adrenalin/amrinonum was required in 40% of the patients in group 3, 5% in group 2 and none in group 1. Group 1 patients had a better improvement of cardiac performance than group 2, while other parameters did not differ. Three months follow up of hospital survivors showed no group differences. Conclusions: The use of preoperative IABP in high risk patients lowers hospital mortality and shortens the stay in ICU, due to improved cardiac performance, compared to a controls. The procedure was cost-beneficial. One day preoperative IABP treatment improves cardiac performance more than 1-2 h preoperative IABP treatment, but does not significantly affect the outcome in terms of hospital mortality or postoperative morbidity. © 1997 Elsevier Science B.V.
Introduction
The intra-aortic balloon pump (IABP) is an established additional support to pharmacological treatment of the failing heart after myocardial infarction, unstable angina and cardiac surgery [1, 9, 14] . Insertion of an IABP in the failing myocardium results in a more favorable myocardial supply/demand balance [11] . Afterload is reduced and diastolic pressure augmented [2, 16] , resulting in an increased stroke volume and cardiac output. Previous studies have demonstrated that the augmented diastolic pressure results in a redistribution of coronary blood flow towards ischemic areas of the myocardium [7, 15] .
Only few studies have so far been published, specifically evaluating the benefits of preoperative intra-aortic balloon pump (IABP) support in 'high-risk' patients [6, 12] . These studies have shown that mortality is significantly lower in preoperatively pumped patients compared to patients receiving the IABP perioperatively [6, 12] .
The aim of the present study was to evaluate the efficacy and the cost-benefit of preoperative IABP treatment on peri-and postoperative cardiac performance, mortality and morbidity and the optimal timing for its insertion, in a controlled prospective randomized manner.
Patients and methods
Between June 1994 and March 1996, 52 high risk patients with coronary artery disease (presenting with two or more of the following criteria: preoperative Left ventricular ejection fraction (LVEF) 540%, left main coronary artery stenosis ]70%, reoperation and/or unstable angina despite medical treatment) underwent myocardial revascularization (CABG). The patients fullfiling the above criteria were randomized into either of three groups by lottery (preprepared closed envelopes containing the group assignement); Group 1 (n =13 patients)-preoperative IABP treatment during 24 h prior to surgery, Group 2 (n = 19 patients)-preoperative IABP treatment during 1-2 h prior to surgery or group 3 (controls, n= 20 patients) where no IABP treatment preoperatively was performed. Group 1 and 2 were chosen in order to evaluate the best timing for preoperative IABP treatment. Cardiac performance was evaluated by cardiac index, calculated from cardiac output data measured repeatedly using a preoperatively inserted Swan-Ganz catheter in all patients and both groups. The amount of pharmacological inotrop support pre-and postoperatively (during the first 12 h) required to maintain an acceptable cardiac index (B 2.0 l/min/m 2 ) was monitored. Postoperative mortality and morbidity as well as required stay in the intensive care unit was registered for each of the groups.
All preoperative clinical, catheterization data and operative data were entered into a computer data base at the time of hospitalization. Definitions were laid prior to the start of the study and were not changed during the study period. LVEF was calculated from the preoperative ventriculography as well as from echocardiography, and from echocardiography during the follow up period.
The mean age was 649 6 years (ranging from 44 to 82 years) and 87% (45 patients) were men, without group differences. All the patients had triple-vessel coronary artery disease and other patient characteristics for each group are presented in Table 1 . Patients who worsened their angina class despite appropriate medication or had angina at rest and/or showed signs of evolving myocardial infarction were regarded to unstable angina.
Twenty patients (38%) underwent urgent surgery (within 24 h of admission), mainly due to unstable angina, despite optimal medical treatment (five patients in group 1, six in group 2 and nine patients in group 3).
In 29 patients (56%) the operation was a reoperative CABG and 24 patients (46%) had a diffuse coronary artery disease, without group differences. A total of 45 patients (87%) had a preoperative LVEF 5 40%, and a brakedown into ejection fraction (EF) categories for each group is shown in Table 1 .
Pre-, per-and postoperatively cardiac output was repeatedly measured, using a Swan-Ganz catheter. Cardiac index (l/min/m 2 ) was calculated for all patients in the study to evaluate cardiac performance.
Anesthesia, cardiopulmonary bypass (CPB) and surgical techniques did not change during the study period and were standardized. Myocardial revascularization was performed during normothermic CPB (35 -37°C). For myocardial protection cold intermittent crystalloid cardioplegia (St Thomas' II, with 1 ml procainamide and 100 mg allopurinol. Initially 1000 ml was infused and thereafter 500 ml every 30 min or whenever electrical activity resumed), together with topical hypothermia with iced slush were employed. As routine the sequential bypass grafting technique was used, earlier described in details [14] . The internal thoracic artery was not routinely used in unstable patients.
The intra-aortic balloon pump
The intra-aortic ballon used was a 9F 40 ml balloon Rediguard ® IAB Catheter (St. Jude Medical, Europe Inc, Zaventem, Belgium, and from 1996 CR Bard Gmbh, Karlsruhe, Germany) connected to a Datascope pump (Datascope, Oakland, NJ, USA). In group 1 all IABPs were inserted using a percutaneous route (femoral artery), preoperatively, in the intensive care unit, on average 24 h prior to the start of cardiopulmonary bypass. Group 2 patient received their IABP (also percutaneously via the femoral artery), preoperatively in the operating room, on average 1.5 h prior to start of the CPB. Group 3 patients received an intraaortic balloon pump in the operating room, if cardiac index \ 2.0 l/min/m 2 could not be maintained, despite triple inotrop drug treatment (dopamin, dobutamine and adrenalin/amrinonum). There was no failure of percutaneous placement of the IABP, while using the guide-wire. Unless heparin was contraindicated, patients undergoing preoperative insertion were therapeutically anticoagulated with heparin after IABP placement. Patients returning from the operating room with an IABP in place where anticoagulated with heparin once mediastinal drainage subsided (usually within 24 h). The IABP support was terminated when hemodynamic stability was restored (maintaning a cardiac index ]2.0 l/min/m 2 with minimal pharmacologic support).
Statistics
Student's t-test (one sample paired test) and Fischer's exact test were employed to assess differences between groups for statistical significance where appropriate. A probability level of PB 0.05 was regarded significant.
Results
The average number of distal anastomoses was 4.3 9 1.5/patient and coronary artery thrombendarterectomy was required, due to diffuse coronary artery disease, in 15 patients (29%), without group differences. Nine patients (17%) only received an internal thoracic artery (ITA) graft in contrast to our normal utilization rate of more than 70% of the patients receiving ITA.
The mean ischemia time did not differ between the groups and was 67.29 20.0 min in group 1, 69.5 917.8 min in group 2 and 72.2917.1 min in group 3. The average cardiopulmonary bypass time was significantly shorter in group 1 and 2 patients, 86.0 9 22.1 min (group 1) and 90.0 9 19.0 min (group 2), compared with controls (group 3), 105.59 26.8, P= 0.014. The time difference between cardiac reperfusion and termination of the extracorporeal circulation was significantly shorter in groups 1 and 2, 19.9 9 7.8 min, compared with controls (Group 3), 31.1 914.7 min, P= 0.002.
Cardiac index data is presented in Table 2 . All measurements of cardiac output were performed without IABP, except in group 1 and group 2 prior to CPB (measurements with IABP). In groups 1 and 2 cardiac index rose significantly after IABP support was introduced, PB 0.001, as expected. However, cardiac index continued to increase between 5 and 30 min after the myocardial revascularization and termination of the CPB, in contrast to group 3 patients were the mean postoperative cardiac index deteriorated during the first 30 min. Measurements at 12 and 24 h showed normalization in all 3 groups, though significantly better in group 1 and 2 compared to group 3 ( Table 2) . Only four patients (13%) in groups 1 and 2 had postoperative low cardiac output and required in addition to pharmacological support further support with IABP. In these patients the IABP could be sucessfully removed 1.39 0.5 days postoperatively. In group 3, 12 patients had postoperative low cardiac output (60%), which was significantly more frequent than observed in group 1 and 2, P B0.05. Eleven of these patient required perioperative insertion of IABP and postoperative IABP treatment in addition to pharmacologic treatment. In group 3, the IABP was needed during a significantly longer time period, 3.19 1.0 days comparison to group 1-2, PB 0.001. There was no IABP related mortality and no IABP complications occurred in this series.
The pharmacological inotrop support was the same in the two groups preoperatively. However, postoperatively patients in group 1 -2 required significantly less pharmacological support than the patients in group 3, 12 h after weaning from CPB ( Table 3 ). The routine in our service is; all patients after myocardial revascularization receive a small dose of dopamin (3 vg/kg/min) during the first 12 h postoperatively.
Hospital mortality in group 1 was 7.7% (1 patient). This patient had preoperative LVEF of 16% developed postoperative low cardiac output, and later was diagnosed to have an acute gangrenous cholecystitis and succumbed due to multiple organ failure on the 17th postoperative day. In group 2 the hospital mortality was 5.9% (1 patient). This patient died due to an uncontrollable hypocoagulopathy 3 days postoperatively. Five patients (25%) died postoperatively in Group 3, which is a significantly higher mortality than the other two groups, PB0.05. All deaths in group 3 were a result of cardiac failure occuring 1 -6 days postoperatively, and only one of these patients had diagnosed myocardial infarction. There were no early graft failures diagnosed in any of the groups. The more risk factors the patient had, the higher was the operative risk. Patients with only two 'high-risk' factors had no hospital mortality in any of the groups. When three 'high-risk' factors were present hospital mortality was 6% (1/16) in group 1-2 compared to 9% (1/11) in group 3. In patients with four 'high-risk' factors mortality rate was 80% (4/5) in group 3 (controls) and only 14% (1/7) in group 1-2. Other postoperative complications were few and evenly distributed between the groups (Table 4 ).
The required period in the intensive care unit was significantly shorter in group 1-2 compared to group 3, 2.39 0.9 days vs. 3.59 1.1 days, PB 0.004.
A cost-benefit analysis (including cost of IABP (device and catheter), intensive care unit stay, drug costs etc.) revealed that preoperative IABP treatment in this high-risk group of patients was cost-beneficial, on average saving 2577 SF/patient in group 2 ( : 2000 USD) and 1327 SF/patient in group 1, compared to the cost/patient calculated in group 3.
Group 1 patients had a better improvement of their cardiac performance than the patients in group 2 (Table  2 ) but other studied parameters did not differ.
A 3-month follow up of hospital survivors revealed no group differences. There were no deaths, LVEF increased and clinically the NYHA-class improved (Table 5 ).
Discussion
Infarct-borne left ventricular dysfunction is increasing the risk of coronary artery bypass surgery [8] . Since its introduction in the 1960s [10] , the intra-aortic balloon pump (IABP) has become the most widely applied method in circulatory support. It is a technique associated with complications, 4-12%, mainly ischemia to the lower limb [3, 6, 12] , most of the time fortuneately reversible after removal of the IABP catheter. In the present series we experienced no catheter related complications. Even though the technique of IABP is associated with a not neglectable morbidity it has been shown to result in great gains in terms of lowered mortality in high risk patients, where hospital mortality is reported to be very high [1, [3] [4] [5] . Most frequently the IABP is used preoperatively [12] , and only few reports on its efficacy as preoperative treatment are available in the literature [5, 6] . The purpose of this study was to evaluate if the use of preoperative intra-aortic balloon pump treatment could improve the outcome after surgical myocardial revascularization, the optimal timing of IABP insertion and if efficient, to evaluate whether this additional treatment is costbeneficial or not. Many desirable hemodynamic effects of the IABP have been demonstrated -augmentation of myocardial perfusion during diastole to increase oxygen delivery to the myocardium, reduction of myocardial oxygen consumption through reduction of left ventricular afterload and left ventricular wall tension and modest increase in cardiac output [2, 13] . Previous studies in hearts with acute coronary occlusion have shown that the augmented diastolic pressure by the IABP results in a redistribution of coronary blood flow towards ischemic areas of the myocardium [7] . Since many of these high risk patients have an energy depletion of the myocardial cells, even a short treatment with IABP would be theoretically beneficial. The factor that leads to hemodynamic recovery in acute pump failure is reversion of ischemic myocardial dysfunction before it yields to cell necrosis, and counterpulsation acts on reversible ischemia.
Indications for preoperative insertion of IABP has usually been reserved for patients with angina refractory to maximal medical therapy or for those with very low cardiac output preoperatively [5] . Creswell et al indicated in their report that it was likely that preoperative IABP insertion was associated with better survival [5] . In a recent report, Dietl and associates have, in a retrospective study, demonstrated that preoperative IABP significantly improve survival, reduce hospital stay and was more cost-effective than no preoperative IABP treatment [6] .
In the present study we have defined 'high risk' patients as a patient fullfilling two or more of the follwing criteria: preoperative LVEF5 40%, Redo-CABG, left main stem coronary artery stensosis ] 70% and or unstable angina despite optimal medical therapy. The three groups studied were similar regarding preoperative patient characteristics, coronary angiography data and operation parameters, without differences statistically, except for the CPB-time, which was significantly longer in group 3 compared to group 1 and 2.
The efficacy of the preoperative IABP treatment was clearly demonstrated in the present series, through an improved cardiac performance (cardiac index) prior to the start of the cardiopulmonary bypass. It is wellknown that the cardiac performance immediately after myocardial revacularization is improved. This was also found in the present study. However, the postoperative improvement in cardiac performance 5 min after termination of CPB was superior in the preoperatively treated IABP group compared to controls. More important is that the cardiac performance continued to improve thereafter in Group 1-2, wheras the control group (Group 3) showed no change or even a slight deterioration in cardiac performance, this in many instances required massive pharamacological support and insertion of a IABP postoperatively. It was also demonstrated that patients preoperatively treated with IABP had a significantly lower mortality rate and a shorter stay in intensive care unit. The total hospital stay did not differ significantly between the groups, but this information is not valid since the majority of our patients are referred from other hospitals and due to pre-arrangements will return to their home hospital after 8-10 days. The procedure was furthermore found cost-beneficial.
It was found that 24 h preoperative treatment with IABP, improved cardiac performance more than 1-2 h preoperative IABP treatment, but does not significantly influence the outcome in terms of hospital mortality, postoperative complications or required stay in intensive care unit. A short preoperative IABP treatment in high-risk patients seems therfore to be the most attrac- a Myocardial infarction was diagnosed if appearance of new Q-vawes or significant loss of R-wave forces, together with peak creatine phosphokinase MB fractions greater than 10% of total creatine phosphokinase. b Transient monopareses. c Acute pancreatitis, one patient, acute gangrenous cholecystitis, one patient. No statistical differences between the groups, except low cardiac output which was significantly more observed in group 3 patients (P = 0.0491). tive alternative, as it is more cost-beneficial, shortening the stay in intensive care. We have since this study applied the shorter treatment alternative.
In conclusion this study has demonstrated a beneficial effect of preoperative IABP treatment in hypertensive patients with coronary artery disease, low LVEF and LV hypertrophy, undergoing CABG. An improved cardiac performance pre-and postoperatively was associated with a lower rate of hospital mortality and less postoperative morbidity, as well as a shorter stay in intensive care unit. The treatment was found costbeneficial and should therefore be recommended as an additional preoperative treatment, but only in patients with calculated high operative risk.
